Paulo Caramelli, MD, PhD, Federal University of Minas Gerais, Belo Horizonte, Brazil, comments on the ongoing debates surrounding the magnitude and clinical significance of the effects of current anti-amyloid therapies for the treatment of Alzheimer’s disease (AD). Dr Caramelli emphasizes the importance of taking care when interpreting the trial results, as although group effects have mostly been positive, it is difficult to prove that the drugs have positive effects on an individual level due to the progressive nature of AD and the lack of symptomatic effects. It is crucial for physicians to discuss the effects of these drugs with patients and families prior to prescribing them, in order to manage expectations and clearly explain the potential long-term benefits and safety concerns associated with the agent of choice. This interview took place at the World Congress of Neurology (WCN) 2023 in Montreal, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
